Skip to content

AnaptysBio

US · ANAB #3010 by market cap Listed 2017
46.63 -0.77 -1.62%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About AnaptysBio

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Founded
2005
CEO
Mr. Daniel R. Faga
Employees
104
Headquarters
San Diego, California, United States of America
Fiscal year end
12-31
Website
anaptysbio.com

Company profile

Exchange
US
Symbol
ANAB
Market-cap rank
#3010
Listing date
2017-01-26
Market cap
1.39B
Float cap
948.03M
Shares out
29.73M
Float shares
20.33M

Sectors & themes

Browse all sectors & themes

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

AnaptysBio discussion 0 comments

Add a comment